

North Central Cancer Treatment Group

N0572: A Phase I/II Study of Sorafenib and CCI-779 in Patients with Recurrent Glioblastoma

Status Change – August 4, 2006

NOTICE OF STATUS CHANGE

This study reopened to patient accrual effective Friday, August 4, 2006 due to the late identification of 1 unevaluable patient. Another patient was immediately identified and the study closed to patient accrual the same day it was reopened, **Friday, August 4, 2006.**

Please retain this notice with the protocol.